Core Viewpoint - The company has approved the 2025 Restricted Stock Incentive Plan and has publicly disclosed the list of incentive recipients, ensuring compliance with relevant regulations and confirming the qualifications of the selected individuals [1][5][7]. Disclosure and Verification - The company disclosed the 2025 Restricted Stock Incentive Plan and related documents on the Shanghai Stock Exchange website on July 12, 2025 [1]. - The public notice period for the proposed incentive recipients lasted 10 days, from July 14 to July 23, 2025, during which employees could provide feedback [2]. - No objections were received regarding the proposed incentive recipients by the end of the public notice period [3]. Verification Process - The Board's Compensation and Assessment Committee verified the incentive recipient list, including checking identification documents and employment contracts [4]. - The committee confirmed that all individuals listed as incentive recipients meet the qualifications set forth by the Company Law and other relevant regulations [5]. - The committee also ensured that none of the proposed recipients fell under disqualifying conditions outlined in the management regulations [6][7]. Eligibility Criteria - The incentive recipients are core employees from the wholly-owned subsidiary, Zhongshan Shengxiang Haiji Biomedical Co., Ltd., and do not include independent directors, supervisors, or major shareholders [7].

证券代码：688289 证券简称：圣湘生物 公告编号：2025-047 圣湘生物科技股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制 性股票激励计划激励对象名单的审核意见及公示 情况说明 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）于 2025 年 7 月 10 日召开了第 二届董事会 2025 年第八次临时会议和第二届监事会 2025 年第五次临时会议，审议通 过了《圣湘生物科技股份有限公司关于<公司 2025 年限制性股票激励计划（草案）> 及其摘要的议案》等议案。根据《上市公司股权激励管理办法》（以下简称"《管理办 法》"）的相关规定，公司对《公司 2025 年限制性股票激励计划（草案）》中确定的 激励对象名单在公司内部进行了公示。公司董事会薪酬与考核委员会根据《管理办法》 相关规定，在征询公示意见后对激励对象名单进行核查，相关公示情况及核查结果如 下： 一、公示情况及核查方式 （一）公示情况 公司于 2025 年 7 月 12 日在上海证券交易所网站（w ...

Group 1 - The capital market for mergers and acquisitions (M&A) is experiencing significant growth, with 200 major asset restructuring projects disclosed by July 15, 2025, since the release of the "M&A Six Guidelines" [1] - The diversity of payment methods has become a prominent feature of the current M&A wave, with the Sci-Tech Innovation Board disclosing 54 M&A transactions in 2023, of which 40% utilized various payment methods including shares and convertible bonds [1][2] - Experts indicate that the innovative application of diversified payment tools has effectively activated the M&A vitality of market participants, enhancing the role of the capital market as the main channel for M&A [1][2] Group 2 - Recent policies such as the "National Nine Guidelines," "Sci-Tech Innovation Board Eight Guidelines," and "M&A Six Guidelines" encourage listed companies to utilize multiple payment tools for M&A [2] - The introduction of flexible payment mechanisms, such as installment payments for share prices, is aimed at increasing transaction flexibility and reducing costs [2][3] - The innovative use of payment tools like targeted convertible bonds and private placements allows companies to complete acquisitions without significantly increasing short-term cash flow pressure [2][4] Group 3 - Targeted convertible bonds are highlighted as a key innovation in M&A, providing a balance between short-term shareholder protection and long-term value binding [3][4] - The flexibility and efficiency of private placements have made them an important means for companies to quickly raise funds and optimize capital structure, thereby enhancing the success rate of M&A [4] - The installment payment mechanism for acquisition prices helps alleviate financial pressure on acquirers and reduces risks associated with one-time valuations [4][8] Group 4 - The Sci-Tech Innovation Board is actively promoting typical M&A cases utilizing diversified payment tools, with notable transactions involving targeted convertible bonds [6] - Companies are increasingly using refinancing funds as a source for acquisitions, balancing the cash exit needs of original shareholders with the financial pressures of listed companies [6] - Recent regulatory changes have allowed for increased loan limits for acquisitions, encouraging companies to pursue M&A more aggressively [7] Group 5 - The introduction of acquisition funds has become a crucial method for companies to alleviate financial pressure and improve M&A success rates [8] - The installment payment mechanism for acquisition prices is designed to lower transaction risks and optimize financial arrangements for listed companies [8] - The recent revision of the "Major Asset Restructuring Management Measures" has formalized the installment payment for share prices, providing more flexibility for companies in arranging payment schedules [8]

Core Viewpoint - The article emphasizes the significant role of the Science and Technology Innovation Board (STAR Market) in driving high-quality development in China's capital market, showcasing its achievements in fostering "hard technology" and innovation over the past six years [1][15]. Group 1: Institutional Framework and Market Dynamics - The STAR Market was established to address critical challenges and facilitate a virtuous cycle between technology, industry, and capital, with a focus on "hard technology" [3]. - A total of 54 companies listed without profitability have found success, with 22 of them turning profitable, highlighting the board's inclusive listing standards [4]. - The STAR Market has attracted over 1.1 trillion yuan in capital through IPOs and refinancing, significantly benefiting key strategic sectors like integrated circuits and biomedicine [5]. Group 2: Innovation and R&D Investment - In 2024, companies on the STAR Market invested a total of 168 billion yuan in R&D, which is more than three times their net profit, indicating a strong commitment to innovation [7]. - The cumulative number of invention patents from STAR Market companies exceeds 120,000, with an average of 216 patents per company, showcasing their innovative capabilities [7]. - Approximately 30% of companies have products or projects that are industry-first, and over 80% focus on achieving import substitution and self-sufficiency [8]. Group 3: Reform and Ecosystem Development - The STAR Market has implemented over 20 key institutional rules to create an optimal capital ecosystem for technological innovation, serving as a model for other markets [10]. - The introduction of the "1+6" policy measures aims to enhance the board's inclusivity and adaptability for various types of hard technology enterprises [14]. - The STAR Market has seen significant activity in mergers and acquisitions, with over 110 new industry mergers reported in the past year, reflecting a dynamic market environment [11]. Group 4: Future Outlook - The STAR Market is poised to further enhance its role in supporting technological self-reliance and the development of new productive forces, with ongoing reforms expected to attract more global innovation elements [15][16].

Core Viewpoint - The company, Hangzhou Deshi Biotechnology Co., Ltd., is preparing for an IPO on the Hong Kong Stock Exchange amid challenges such as declining core business growth, reduced gross margins, and significant financial pressures [1][10]. Company Background - The founder, Dr. Song Ning, has a strong academic background in computer science and medical genetics, with experience teaching at Nagasaki University and Shanghai Jiao Tong University [2]. - Deshi Biotechnology was founded in September 2016 with a registered capital of 1 million yuan, and Song initially held 90% of the shares [3]. Financial Performance - The company reported a total revenue of 70.35 million yuan for 2024, but core business revenue decreased from 43.90 million yuan to 40.84 million yuan, with gross margin dropping by 19.9 percentage points to 56.7% [8]. - The company faced net losses of 56.12 million yuan in 2023 and 43.38 million yuan in 2024, with cash and cash equivalents dwindling to approximately 556,700 yuan by April 2025 [10][11]. Market Position - Deshi Biotechnology holds a leading position in the Chinese chromosome karyotype analysis system market, with a market share of 30.6% [7]. - The overall market for chromosome karyotype analysis is expected to grow from 120 million yuan in 2019 to 166 million yuan by 2024, with a compound annual growth rate of 6.7% [7]. Strategic Moves - The company has divested two subsidiaries for 1 yuan each to streamline operations and focus on core business, although the financial details of these subsidiaries were not disclosed [5][7]. - Deshi Biotechnology is betting on its AI-driven diagnostic system, AI AutoVision®, which has received "innovative medical device" recognition and is crucial for the company's future performance [11]. Investment and Shareholding - The company has attracted multiple rounds of investment, with a post-investment valuation reaching 2.56 billion yuan as of June 2025 [4]. - Song Ning has successfully executed several share buybacks to maintain control, currently holding 30.04% directly and controlling 52.06% of voting rights through various platforms [3][4].

Core Points - The company is holding its third extraordinary general meeting of shareholders in 2025 to discuss several key proposals, including a restrictive stock incentive plan and changes to its governance structure [1][2][3] Group 1: Shareholder Meeting Procedures - Shareholders and their representatives must sign in 15 minutes before the meeting and present identification to attend [1][2] - The meeting will follow a structured agenda, allowing shareholders to exercise their rights to speak, inquire, and vote [2][3] - Voting will be conducted both on-site and online, with specific time frames for participation [4][5] Group 2: Proposals for Consideration - Proposal 1 involves the approval of the 2025 restrictive stock incentive plan, which aims to attract and retain key employees by granting a total of 1.1926 million shares [7][8] - Proposal 2 focuses on the implementation assessment management measures for the restrictive stock incentive plan [9] - Proposal 3 seeks authorization for the board to manage matters related to the restrictive stock incentive plan [10][11] Group 3: Governance Changes - Proposal 4 suggests abolishing the supervisory board and revising the company's articles of association to enhance governance [13][14] - Proposal 5 involves the election of the third board of directors, with specific candidates nominated for non-independent director positions [16] - Proposal 6 addresses the nomination of independent directors for the third board of directors [18][19]

圣湘生物科技股份有限公司 2025 年第三次临时股东大会会议资料 二〇二五年七月 圣湘生物科技股份有限公司（688289）2025 年第三次临时股东大会会议资料 目录 | 年第三次临时股东大会会议须知 2025 | 2 | | --- | --- | | 2025 年第三次临时股东大会会议议程 | 4 | | 议案一：圣湘生物科技股份有限公司关于《公司 年限制性股票激励计划（草 2025 | | | 案）》及其摘要的议案 | 6 | | 议案二：圣湘生物科技股份有限公司关于《公司 2025 年限制性股票激励计划实 | | | 施考核管理办法》的议案 | 7 | | 议案三：圣湘生物科技股份有限公司关于提请股东大会授权董事会办理公司限制 | | | 性股票激励计划相关事宜的议案 | 8 | | 议案四：圣湘生物科技股份有限公司关于不再设置监事会、修订《公司章程》并 | | | 办理工商变更登记及制定、修订部分治理制度的议案 | 10 | | 议案五：圣湘生物科技股份有限公司关于董事会换届选举暨提名第三届董事会非 | | | 独立董事候选人的议案 | 11 | | 议案六：圣湘生物科技股份有限公司关于董事会换届选 ...

Core Insights - The article highlights the rapid growth and strategic importance of the nano-metal materials industry in China, driven by technological advancements and increasing market demand [1][14]. Industry Overview - Nano-metal materials, characterized by grain sizes between 1-100 nanometers, exhibit superior properties such as ultra-high strength, excellent thermal stability, and unique electromagnetic characteristics [1][14]. - The market size for nano-metal materials in China is projected to grow from 28.98 billion yuan in 2018 to 74.451 billion yuan in 2024, with a compound annual growth rate (CAGR) of 17.03% [1][14]. - Key applications of nano-metal materials include electronics, new energy development, biomedicine, and aerospace [1][14]. Production Methods - The production methods for nano-metal materials are categorized into physical and chemical methods, including evaporation-condensation, high-energy ball milling, and chemical reduction [5]. Policy Support - The Chinese government has identified nano-materials as a key area for development, with various policies aimed at promoting innovation and industrial upgrades [7]. Industry Chain - The upstream of the nano-metal materials industry includes raw material supply and manufacturing equipment, while the downstream encompasses applications in biomedical, aerospace, construction, automotive, and electronics sectors [9]. Key Companies - Notable companies in the nano-metal materials sector include Jiangsu Boqian New Materials Co., Ltd., Jiangxi Baohong Nano Technology Co., Ltd., and Shandong Changxin Nano Technology Co., Ltd., which are involved in the R&D and production of high-performance nano-metal materials [17][19][21]. Development Trends - The industry is moving towards high-performance and multifunctional materials, with innovations in atomic-level structure design and surface modification technologies [25]. - There is a shift towards green and low-carbon production methods, emphasizing sustainable practices in the manufacturing of nano-metal materials [26][27]. - Cross-disciplinary integration is expanding the application boundaries of nano-metal materials, particularly in biomedicine and information technology [28].

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Group 1 - The A-share market has seen increased activity in mergers and acquisitions (M&A) since the release of the "Six M&A Guidelines," with over 200 new major asset restructuring projects disclosed [1] - A notable feature of this M&A wave is the diversification of payment methods, with companies utilizing shares, convertible bonds, private placements, acquisition loans, and M&A funds [1] - The new policies, including the "National Nine Articles," "Sci-Tech Innovation Board Eight Articles," and "Six M&A Guidelines," encourage listed companies to use various payment tools for M&A [1] Group 2 - Listed companies can use refinancing funds as a source for acquisition financing, often disclosing refinancing plans alongside acquisition proposals [2] - For example, Lingyun Optical announced a cash acquisition of JAI A/S for €1.03 billion and subsequently disclosed a fundraising plan of 785 million yuan to cover the transaction [2] - The financial regulatory authority has relaxed M&A loan requirements, increasing the loan cap from 60% to 80% of the transaction price for controlling acquisitions [2] Group 3 - The introduction of M&A funds has become a significant method for companies to alleviate financial pressure and enhance the success rate of acquisitions [3] - Companies are also employing installment payment mechanisms for acquisition consideration, such as the earn-out mechanism used by Shengxiang Biology in its acquisition of a 100% stake in a biopharmaceutical company [3] - Recent revisions to restructuring management regulations have formalized the installment payment of share consideration, extending the validity period of registration documents to 48 months [3]